The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Open accessAbstract
Purpose: This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. Patients and Methods: Patients were randomly assigned in a 1:1 ratio to linifanib 17.5 mg once daily or sorafenib 400 mg twice daily. Patients were stratified by region (Outside Asia, Japan, and rest of Asia), Eastern Cooperative Oncology Group performance score (ECOG PS; 0 or 1), vascular invasion or extrahepatic spread (yes or no), and hepatitis B virus (HBV) infection (yes or no). The primary end point of the study was overall survival (OS). Secondary end points were time to progression (TTP) and objective response rate (ORR) per RECIST v1.1. Results: We randomly assigned 1,035 patients (median age, 60 years; Asian, 66.6%; ECOG PS 0, 65.2%; HBV, 49.1%; vascular invasion or extrahepatic spread, 70.1%). Median OS was 9.1 months on the linifanib arm (95% CI, 8.1 to 10.2) and 9.8 months on the sorafenib arm (95% CI, 8.3 to 11.0; hazard ratio [HR], 1.046; 95% CI, 0.896 to 1.221). For prespecified stratification subgroups, OS HRs ranged from 0.793 to 1.119 and the 95% CI contained 1.0. Median TTP was 5.4 months on the linifanib arm (95% CI, 4.2 to 5.6) and 4.0 months on the sorafenib arm (95% CI, 2.8 to 4.2; HR, 0.759; 95% CI, 0.643 to 0.895; P = .001). Best response rate was 13.0% on the linifanib arm versus 6.9% on the sorafenib arm. Grade 3/4 adverse events (AEs); serious AEs; and AEs leading to discontinuation, dose interruption, and reduction were more frequent with linifanib (all P < .001). Conclusion: Linifanib and sorafenib had similar OS in advanced HCC. Predefined superiority and noninferiority OS boundaries were not met for linifanib and the study failed to meet the primary end point. TTP and ORR favored linifanib; safety results favored sorafenib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 3×
“9%) each compare favorably to previous phase III trials of sorafenib in advanced HCC patients.(21,23) Unfortunately, the improvements in TTP, PFS, and ORR did not translate to improvements in OS, a finding that has been reported with another antiangiogenic agent in the treatment of HCC.”
ResultSelf-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Imamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
Molecular mechanisms of blood vessel growth
Conway, E. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00281-9 · Cited by 1,030
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Self-citationJohnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Self-citationA general parametric approach to the meta‐analysis of randomized clinical trials
Whitehead, A., & Whitehead, J. (1991) · Statistics in Medicine · doi:10.1002/sim.4780101105 · Cited by 750
Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Self-citationZhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Self-citationSantoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70490-4 · Cited by 554
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Expression of vascular endothelial growth factor in human hepatocellular carcinoma
Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510280111 · Cited by 397
International trends and patterns of primary liver cancer
McGlynn, K. A., Tsao, L., Hsing, A. W., Devesa, S. S., & Fraumeni, J. F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1456 · Cited by 349
Tugues, S., Fernandez-Varo, G., Muñoz-Luque, J., Ros, J., Arroyo, V., Rodés, J., Friedman, S. L., Carmeliet, P., Jiménez, W., & Morales-Ruiz, M. (2007) · Hepatology · doi:10.1002/hep.21921 · Cited by 261
Design and analysis of non‐inferiority mortality trials in oncology
Rothmann, M., Li, N., Chen, G., Chi, G. Y. H., Temple, R., & Tsou, H. (2003) · Statistics in Medicine · doi:10.1002/sim.1400 · Cited by 243
Poon, R. T. P., Ho, J. W. Y., Tong, C. S. W., Lau, C., Ng, I. O. L., & Fan, S.-T. (2004) · British Journal of Surgery · doi:10.1002/bjs.4594 · Cited by 228
Kirk, G. D., Lesi, O. A., Mendy, M., Akano, A. O., Sam, O., Goedert, J. J., Hainaut, P., Hall, A. J., Whittle, H., & Montesano, R. (2004) · Hepatology · doi:10.1002/hep.20027 · Cited by 210
Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma
Miura, H., Miyazaki, T., Kuroda, M., Oka, T., Machinami, R., Kodama, T., Shibuya, M., Makuuchi, M., Yazaki, Y., & Ohnishi, S. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80323-6 · Cited by 158
Wada, H., Nagano, H., Yamamoto, H., Yang, Y., Kondo, M., Ota, H., Nakamura, M., Yoshioka, S., Kato, H., Damdinsuren, B., et al. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01243.x · Cited by 130
Toh, H. C., Chen, P., Carr, B. I., Knox, J. J., Gill, S., Ansell, P. J., McKeegan, E. M., Dowell, B. L., Pedersen, M., Qin, Q., et al. (2012) · Cancer · doi:10.1002/cncr.27758 · Cited by 115
Self-citationZhang, T., Sun, H., Xu, Y. Y., Zhang, K., Wang, L., Qin, L., Wu, W., Liu, Y., Ye, S., & Tang, Z. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0944 · Cited by 97
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Zhou, J., Goh, B.-C., Albert, D. H., & Chen, C.-S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-33 · Cited by 65
Research works printed but not linked: 1
- Zhu AX, 37th European Society for Medical Oncology Congress
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationKudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationForner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Metadata
- Authors
- Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., Gorbunova, V., Eskens, F. A. L. M., Qian, J., McKee, M. D., Ricker, J. L., Carlson, D. M., & El-Nowiem, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-01-10
- Volume
- 33
- Issue
- 2
- Pages
- 172-179
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120967735
- Cited by
- 629
- References
- 35
- FWCI
- 29.26
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-08-01)
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.